California is currently home to 5602 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)
NCT05020535
Recruiting
This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Stanford University, Palo Alto, California
Conditions: Intracerebral Hemorrhage
Register for Updates
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933
Recruiting
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
12/09/2024
Locations: Precision NextGen Oncology and Research, Beverly Hills, California
Conditions: Colorectal Adenocarcinoma, Ewing Sarcoma
Register for Updates
Electroacupuncture in Symptom Management After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
NCT06340906
Recruiting
The investigators are conducting this research study is to evaluate the feasibility (recruitment, compliance, safety, and acceptance) of using electroacupuncture (EA) to manage complex symptoms such as pain, nausea/vomiting, diarrhea, and insomnia in patients who have undergone Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Additionally, the investigators are aiming to determine the effectiveness of EA in reducing these symptoms, and to examine how EA impacts important biom... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/08/2024
Locations: UCI Health Susan Samueli Integrative Health Institute, Irvine, California
Conditions: Cancer
Register for Updates
Multicenter Evaluation of Near Vision and Outdoor Time in Kids Study
NCT06119243
Recruiting
Currently, optical and pharmacological interventions have been developed to prevent the progression of childhood myopia. However, no myopia control strategy has been shown to have complete efficacy in controlling myopia progression in children. One possible reason is that risk factors contributing to the development of myopia were not controlled in previous clinical studies including time outdoors and near vision behaviour. This study aims to quantify time spent outdoors and near vision behavior... Read More
Gender:
ALL
Ages:
Between 4 years and 14 years
Trial Updated:
12/08/2024
Locations: School of Optometry, University of California, Berkeley, Berkeley, California
Conditions: Myopia
Register for Updates
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
NCT06665971
Recruiting
The goal of this study is to research Dupilumab, an FDA approved medication in treating patients diagnosed with Eosinophilic esophagitis (EoE). The drug works by controlling allergic inflammation of the esophagus. The esophagus is a food pipe that transfers food from the mouth into the stomach. Participants with EoE have dysfunction of the muscle of the esophagus (impaired peristalsis) that is not favorable for the transport function. Main question this study aims to answer is: Whether Dupiluma... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
12/06/2024
Locations: University of California San Diego (UCSD) Health Medical center, La Jolla, California
Conditions: Eosinophilic Esophagitis (EoE)
Register for Updates
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
NCT06049576
Recruiting
This phase I trial tests the safety, side effects, and best dose of camu camu when used in combination with nivolumab and ipilimumab in treating patients with kidney cancer that has spread to other places in the body. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
NCT06018766
Recruiting
The goal of this clinical trial is to learn about the safety and effectiveness of LAM-001 in patients who have developed bronchiolitis obliterans syndrome (BOS), a form of chronic rejection, after lung transplantation. The main questions it aims to answer are: * Is LAM-001 safe in these patients? * Is LAM-001 effective in slowing BOS progression? Participants will: * Be randomly assigned to inhale either LAM-001 or placebo (a look-alike substance that contains no active drug) daily for 48 we... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction, Lung Transplantation
Register for Updates
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
NCT05746208
Recruiting
This is the first study to be done in a newly described class of neuroendocrine tumors known as well-differentiated grade 3 neuroendocrine tumors (WD G3 NET). First described in the pancreas in 2017, the classification was broadened to include gastrointestinal tract tumors in 2019. Recent data suggest an equivalent subtype exists in the lungs (NEC with carcinoid morphology). WD G3 NETs can occur de novo as well as the result of grade progression over time. This is a single arm, multi-site, Phase... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
Register for Updates
Silicone Gel Vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause
NCT05672901
Recruiting
The goal of this randomized controlled trial is to test the efficacy of StrataMGT in the management of Genitourinary Syndrome of Menopause (GSM) compared to estrogen therapy. The main question it aims to answer is: - Will StrataMGT be non-inferior regarding patient quality of life compared to standard of care? Participants will use either StrataMGT or estrogen vaginal cream to treat GSM for 3 consecutive months. After the baseline assessment, participants will be assessed monthly for quality o... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Orange Coast Women's Medical Group, Laguna Hills, California
Conditions: Genitourinary Syndrome of Menopause
Register for Updates
Rapid Acting TMS for Suicide Ideation in Depression
NCT05100004
Recruiting
This study evaluates the effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), on the neural networks underlying explicit and implicit suicidal cognition in inpatients with major depressive disorder.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/06/2024
Locations: Stanford Hospital, Stanford, California
Conditions: Depressive Disorder, Major, Suicide
Register for Updates
Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder with RTMS
NCT04870255
Recruiting
This study evaluates the antidepressant effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), in individuals with borderline personality disorder (BPD) or trait and comorbid mood depressive disorder (MDD) or bipolar II disorder in a current mood depressive episode (MDE).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/06/2024
Locations: Stanford Hospital, Stanford, California
Conditions: Depressive Disorder, Major, Borderline Personality Disorder
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRĪ±)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556
Recruiting
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \[OC\], endometrial cancer \[EC\], non-small cell lung carcinoma \[NSCLC\], triple-negative breast cancer \[TNBC\]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Solid Tumor
Register for Updates